Sputum Culture Conversion With Moxifloxacin-Containing Regimens in the Treatment of Patients With Newly Diagnosed Sputum-Positive Pulmonary Tuberculosis in South India
Authors:
Open Access
- 14 July 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 59 (10) , e142-e149
Abstract
A 5-drug daily regimen of moxifloxacin, rifampicin, isoniazid, pyrazinamide, and ethambutol resulted in significantly higher sputum culture conversion at 2 months compared with thrice-weekly rifampicin, isoniazid, pyrazinamide, and ethambutol in newly diagnosed, sputum-positive, HIV-uninfected pulmonary tuberculosis patients in south India. Background. Rapid sputum culture conversion at 2 months indicates the sterilizing capacity and potential of regimens to shorten duration of tuberculosis treatment. We compared results of sputum culture conversion by moxifloxacin and control regimens and identified factors affecting sputum culture positivity after 2 months of treatment. Methods. Human immunodeficiency virus–uninfected adults with newly diagnosed smear-positive pulmonary tuberculosis were randomized to receive a 3- or 4-month moxifloxacin regimen (moxifloxacin [M], isoniazid [H], rifampicin [R], pyrazinamide [Z], ethambutol [E]) or the control regimen (RHZE thrice weekly). Bacteriological assessments were done at 15, 30, 45, and 60 days of treatment. Because all patients in the moxifloxacin groups received 2 months of daily RHZEM, they were grouped together for analysis. Statistical methods included χ2 test and logistic regression analysis. Results. Sputum culture conversion was analyzed in 780 (616 in the moxifloxacin group and 164 in the control group) of 801 enrolled patients. Ninety-five percent of 590 patients in the moxifloxacin group and 81% of 151 patients in the control group had negative sputum cultures at month 2 (P < .001). The control regimen, age (≥35 years), initial sputum culture grade (2+ or 3+), and male sex were significantly associated with higher odds of positive sputum cultures at 2 months. Conclusions. A 5-drug daily regimen with moxifloxacin results in significantly higher sputum culture conversion in the first 2 months compared with a thrice-weekly, 4-drug regimen in patients with newly diagnosed sputum-positive pulmonary tuberculosis.Keywords
This publication has 16 references indexed in Scilit:
- Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis PatientsPLOS ONE, 2013
- Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trialThe Lancet, 2004
- Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine TuberculosisAntimicrobial Agents and Chemotherapy, 2002
- Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 MonthsAmerican Review of Respiratory Disease, 1993
- Comparison of various measures of sensitivity of M. tuberculosis to ethambutolTubercle, 1978